Group 1 - Halper Sadeh LLC is investigating potential violations of federal securities laws and breaches of fiduciary duties related to the sale of Penumbra, Inc. to Boston Scientific Corporation for $374.00 in cash or 3.8721 shares of Boston Scientific common stock [1] - RAPT Therapeutics, Inc. is being investigated for its sale to GSK plc for $58.00 per share [2] - The firm may seek increased consideration for shareholders, additional disclosures, and other relief on behalf of shareholders, operating on a contingent fee basis [3] Group 2 - Shareholders are encouraged to contact Halper Sadeh LLC free of charge to discuss their legal rights and options [4] - Halper Sadeh LLC represents investors globally who have experienced securities fraud and corporate misconduct, recovering millions for defrauded investors [4]

Core Insights - GSK plc has entered into a definitive agreement to acquire RAPT Therapeutics for an estimated equity value of $2.2 billion, which will enhance GSK's pipeline with RAPT's ozureprubart, a long-acting anti-IgE monoclonal antibody currently in phase IIb study for food allergy protection [1][6]. Company Summary - The acquisition is expected to close in the first quarter of 2026 and will strengthen GSK's respiratory, immunology, and inflammation pipeline [2][6]. - GSK will pay $58.00 per share to RAPT's shareholders, resulting in an upfront investment of $1.9 billion after accounting for cash acquired [4][6]. - GSK will gain global rights to the ozureprubart program, excluding certain regions in Asia, and will be responsible for success-based milestones and royalties to RAPT's partner [7]. Product Development - Ozureprubart is currently being evaluated in a phase IIb study for prophylactic protection against food allergens, with data expected in 2027 and phase III studies planned for at-risk adult and pediatric populations [8]. - The product is anticipated to enhance GSK's commercial presence in the allergy space, offering potentially less frequent dosing compared to current treatments [9]. Industry Context - The biotech and pharma sector is experiencing a surge in merger and acquisition activity as companies seek to diversify revenue streams amid declining sales of flagship drugs [10]. - Recent notable acquisitions in the industry include Merck's acquisition of Cidara Therapeutics for approximately $9.2 billion and J&J's acquisition of Halda Therapeutics for $3.05 billion, indicating a trend towards portfolio expansion and innovation [11][12].

Company Highlights - Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has experienced a 76.53% increase in its stock price, reaching $4.62, attributed to progress in its drug pipeline, particularly the Phase 1b trial for ATI-052 targeting atopic dermatitis [1][5] - Corvus Pharmaceuticals, Inc. (CRVS) has seen a remarkable 142.73% increase, with its stock price hitting $19.54, driven by promising results in its eczema treatment and a focus on immuno-oncology therapies, especially its lead product candidate, Mupadolimab [2][5] - RAPT Therapeutics, Inc. (RAPT) saw its stock price increase by 63.83% to $57.50, despite an investigation into potential breaches of fiduciary duty, with investor interest driven by promising drug candidates like RPT193 and FLX475 [3] Market Overview - Recent market movements highlight the dynamic nature of the stock market, with companies across different sectors experiencing rapid changes in valuations [4]

Group 1 - The National Development and Reform Commission (NDRC) will unify subsidy standards for "two new" categories, including vehicle scrappage and replacement, as well as various electronic products, to implement a nationwide unified market requirement [2] - The NDRC is planning to promote a series of significant high-tech industry projects during the 14th Five-Year Plan period, with expectations for the digital economy's added value to reach 49 trillion yuan by 2025, accounting for approximately 35% of GDP [3] - The Ministry of Finance will provide financial subsidies for loans related to technological innovation, supporting the upgrade of key industries and the digital transformation of small and medium-sized enterprises [4] Group 2 - Starting February 1, micro, light, and small drones will not require reporting for flights in suitable airspace in Shanghai, while flights in controlled airspace will need approval from air traffic management [5][6] - Domestic refined oil prices are set to increase for the first time in 2026, with an expected rise of about 90 yuan per ton, leading to an additional cost of approximately 4 yuan for filling a 70-liter tank [7] - GAC Group clarified that rumors regarding the replacement of half of its automotive chips with those from Gree Electric are not true, following a meeting between executives from both companies [8] Group 3 - The unicorn company "Moon's Dark Side" is undergoing a new financing round with a pre-investment valuation of nearly $4.8 billion, following a recent $500 million Series C funding round [9] - Among three Japanese automakers in China, only Toyota announced a sales increase for 2025, projecting over 1.78 million units sold, while Nissan and Honda reported continuous declines [10] - New Oriental has hired Chen Xingjia as a senior consultant with an annual salary of 1.5 million yuan, while also committing to donate at least 1 million yuan annually to the Henghui Public Welfare Foundation [11] Group 4 - Germany has reintroduced electric vehicle purchase subsidies, offering up to 6,000 euros for new electric vehicles to stimulate domestic industry, applicable to vehicles registered from January 1, 2026 [12] - Elon Musk's social media platform X has open-sourced its recommendation algorithm, relying heavily on AI for content filtering and ranking [12] - Analysts predict that OpenAI could achieve nearly $25 billion in annual advertising revenue by 2030, based on the anticipated scale of ChatGPT and its marketing capabilities [14]

Group 1 - Rapt Therapeutics' shares increased over 60% following the announcement of its acquisition by GSK for $2.2 billion [1] - Investors in Rapt will receive $58.00 per share, representing a premium of over 65% compared to the closing price on January 16, prior to the acquisition announcement [3] - The acquisition grants GSK global rights to ozureprubart, an experimental antibody treatment for food allergies, which is currently in phase 2 clinical trials [4] Group 2 - There is a significant unmet need for treatments targeting food allergies, with over 17 million people affected in the U.S., including 1.3 million with severe reactions [6] - Rapt's investigational treatment targets a protein responsible for approximately 94% of severe food allergies, indicating its potential impact on public health [6] - The deal is expected to close in the first quarter, pending regulatory approval [5]

Economic Indicators - December pending home sales are expected to decline by -0.5% month-over-month [1] - Initial weekly unemployment claims are projected to increase by +12,000 to 210,000 [1] - Q3 GDP is anticipated to remain unchanged at +4.3% quarter-over-quarter annualized [1] - November personal spending is expected to rise by +0.5% month-over-month, while personal income is projected to increase by +0.4% month-over-month [1] - The November core PCE price index is expected to rise by +0.2% month-over-month and +2.8% year-over-year [1] - January S&P US manufacturing PMI is expected to increase by +0.2 to 52.0 [1] - The final University of Michigan January US consumer sentiment index is expected to remain unchanged at 54.0 [1] Stock Market Movements - US natural gas-producing stocks surged as natural gas prices increased by more than +26% to a three-week high [2][16] - Gold and silver mining stocks experienced significant gains due to safe-haven buying, with prices reaching all-time highs [2][15] - Stock indexes fell sharply, with the S&P 500 down -2.06%, Dow Jones down -1.76%, and Nasdaq 100 down -2.12% [4] - The Magnificent Seven technology stocks saw declines, with Nvidia and Tesla down more than -4% [13] - Defensive beverage makers rose amid the broader market decline, with Monster Beverage and Constellation Brands both up more than +4% [17] Earnings Reports - Q4 earnings season has begun positively, with 88% of the 33 S&P 500 companies that reported beating expectations [5] - S&P earnings growth is expected to increase by +8.4% in Q4, while excluding the Magnificent Seven, growth is expected at +4.6% [5] Bond Market - Rising bond yields impacted stocks, with the 10-year T-note yield reaching a 4.75-month high of 4.31% [3][8] - The 10-year Japanese government bond yield rose to a 27-year high of 2.359% due to fiscal concerns [3][9] - The markets are currently discounting a 5% chance of a -25 basis point rate cut at the next FOMC meeting [6] International Markets - Overseas stock markets closed lower, with the Euro Stoxx 50 down -0.57% and China's Shanghai Composite down -0.01% [7]

Market Overview - U.S. stocks experienced a decline, with the Nasdaq Composite falling 1.5% amid President Trump's tariff threats related to the Greenland dispute [1] - The Dow decreased by 1.17% to 48,780.92, while the S&P 500 dropped 1.32% to 6,848.33 [1] - European shares also fell, with the eurozone's STOXX 600 down 0.92% and major indices in Spain, London, Germany, and France experiencing declines [8] Company Earnings - D.R. Horton, Inc. reported net income of $594.8 million, or $2.03 per diluted share, for Q1 of fiscal 2026, down from $844.9 million, or $2.61 per diluted share, in the same quarter last year [3] - Revenue for D.R. Horton was $6.887 billion, a decrease from $7.613 billion year-over-year, but exceeded the consensus estimate of $6.603 billion [4] Stock Movements - Rapt Therapeutics Inc shares surged 64% to $57.52 following GSK's announcement of an acquisition [9] - Corvus Pharmaceuticals Inc shares increased by 107% to $16.66 after positive clinical trial results [9] - Immunitybio Inc shares rose 23% to $6.78 after a meeting with the FDA regarding its application for a cancer treatment [9] - Bakkt Holdings Inc shares fell 19% to $17.42 after announcing a $300 million ATM equity program [9] - NovaBay Pharmaceuticals Inc shares dropped 45% to $8.07 following a stock offering announcement [9] - Synlogic Inc shares decreased by 38% to $0.70 after receiving a Nasdaq delisting notification [9] Commodities - Oil prices increased by 2% to $60.62, while gold rose by 3.6% to $4,759.30 [7] - Silver saw a significant increase of 7.1% to $94.845, whereas copper fell by 0.8% to $5.7845 [7]

Economic Indicators - December pending home sales are expected to decline by -0.5% month-over-month [1] - Initial weekly unemployment claims are projected to increase by +12,000 to 210,000 [1] - Q3 GDP is anticipated to remain unchanged at +4.3% quarter-over-quarter annualized [1] - November personal spending is expected to rise by +0.5% month-over-month, while personal income is projected to increase by +0.4% month-over-month [1] - The November core PCE price index is expected to rise by +0.2% month-over-month and +2.8% year-over-year [1] - January S&P US manufacturing PMI is expected to increase by +0.2 to 52.0 [1] - The final University of Michigan January US consumer sentiment index is expected to remain unchanged at 54.0 [1] Stock Market Movements - US natural gas-producing stocks surged over +25% to a three-week high, with companies like Coterra Energy up more than +3% [2][15] - Gold and silver mining stocks are climbing as prices reach all-time highs, with Newmont Mining up more than +3% and Barrick Mining up more than +2% [2][14] - The S&P 500, Dow Jones Industrials, and Nasdaq 100 indexes fell to two-week lows, with declines of -1.23%, -1.07%, and -1.36% respectively [4] - The Magnificent Seven technology stocks are experiencing declines, with Nvidia and Tesla down more than -2% [12] - Cryptocurrency-exposed stocks are also down, with Bitcoin falling more than -2% [13] Earnings Reports - 88% of the 33 S&P 500 companies that have reported earnings so far have beaten expectations, with S&P earnings growth expected to climb by +8.4% in Q4 [5] - Excluding the Magnificent Seven, Q4 earnings are expected to increase by +4.6% [5] - 3M Co. is down more than -7% after forecasting 2026 adjusted EPS below consensus [16] - Fastenal reported Q4 net sales of $2.03 billion, below the consensus of $2.04 billion, leading to a decline of more than -4% [16] Bond Market - The 10-year T-note yield rose to a 4.75-month high of 4.31%, influenced by rising bond yields and concerns about an independent Fed [3][8] - Rising inflation expectations are bearish for T-notes, with the 10-year breakeven inflation rate climbing to a 3.25-month high of 2.342% [8] - European government bond yields are also increasing, with the 10-year German bund yield rising to a two-week high of 2.894% [10]

Market Overview - U.S. stocks experienced a decline, with the Dow Jones falling approximately 700 points on Tuesday [1] Corvus Pharmaceuticals - Corvus Pharmaceuticals Inc saw a significant increase in share price, rising 90.3% to $15.32 after announcing positive results from cohort 4 of a Phase 1 clinical trial for soquelitinib in patients with moderate to severe atopic dermatitis [1] Rapt Therapeutics - Rapt Therapeutics Inc's shares surged 63.8% to $57.52 following the announcement of its acquisition by GSK [2] Immunitybio - Immunitybio Inc's stock increased by 24.3% to $6.86 after the company held a Type B End-of-Phase meeting with the FDA regarding its supplemental Biologics License Application for ANKTIVA plus Bacillus Calmette-Guérin in treating BCG-unresponsive non-muscle invasive bladder cancer with papillary tumors [2] Acadia Healthcare - Acadia Healthcare Company Inc's shares rose 21.2% to $14.15 after the appointment of Debbie Osteen as CEO and reaffirmation of its FY25 guidance [2] Other Notable Stocks - Titan Mining Corp gained 20.2% to $4.89 [2] - United Microelectronics Corp increased by 15.8% to $10.78 [2] - Korea Electric Power Corp's shares rose 15.7% to $21.71 [2] - Iamgold Corp surged 14.6% to $19.69, reporting preliminary 2025 operating results with gold production of 765,900 ounces and 2026 guidance targeting 720,000 to 820,000 ounces [2] - Hycroft Mining Holding Corporation increased by 12.2% to $38.85 [2] - SK Telecom Co Ltd jumped 10.2% to $23.12 [2] - USA Rare Earth Inc gained 10.1% to $19.48, planning to develop a 3,750 mtpa metal and alloy production facility in Lacq, France [2] - Lumentum Holdings Inc surged 7.1% to $347.31 [2] - SanDisk Corp rose 7% to $442.51 [2]

Economic Indicators - December pending home sales are expected to decline by -0.5% month-over-month [1] - Initial weekly unemployment claims are projected to increase by +12,000 to 210,000 [1] - Q3 GDP is anticipated to remain unchanged at +4.3% quarter-over-quarter annualized [1] - November personal spending is expected to rise by +0.5% month-over-month, while personal income is expected to increase by +0.4% month-over-month [1] - The November core PCE price index is forecasted to rise by +0.2% month-over-month and +2.8% year-over-year [1] - January S&P US manufacturing PMI is expected to increase by +0.2 to 52.0 [1] - The final University of Michigan January US consumer sentiment index is expected to remain unchanged at 54.0 [1] Stock Market Performance - The S&P 500 Index is down -1.29%, the Dow Jones Industrials Index is down -1.22%, and the Nasdaq 100 Index is down -1.41% [5] - Overseas stock markets are also lower, with the Euro Stoxx 50 down -1.17%, China's Shanghai Composite down -0.01%, and Japan's Nikkei Stock 225 down -1.11% [8] Earnings Reports - Q4 earnings season has begun positively, with 88% of the 33 S&P 500 companies that have reported beating expectations [6] - S&P earnings growth is expected to increase by +8.4% in Q4, while excluding the Magnificent Seven technology stocks, growth is expected to be +4.6% [6] Commodity and Sector Movements - US natural gas-producing stocks are surging as natural gas prices have increased by more than +25% to a 3-week high [2][16] - Gold and silver mining stocks are climbing as gold and silver prices reach all-time highs, with companies like Hecla Mining and Coeur Mining up more than +4% [2][15] - The Magnificent Seven technology stocks are declining, with Nvidia down more than -3% and other major players like Amazon and Tesla down more than -2% [13] Bond Market - Rising bond yields are impacting stocks, with the 10-year T-note yield reaching a 4.75-month high of 4.31% [3] - The 10-year Japanese government bond yield has risen to a 27-year high of 2.359% due to fiscal concerns [3][9] - The 10-year T-note yield is up by +6.2 basis points to 4.285% [9] Company-Specific News - 3M Co. is down more than -5% after forecasting 2026 adjusted EPS below consensus [17] - RAPT Therapeutics is up more than +62% after GSK Plc agreed to acquire the company for approximately $2.2 billion [18] - Micron Technology is up more than +4% after a price target increase by Stifel [18] - Intel is up more than +2% following an upgrade by Seaport Global Securities [19] - Netflix is up more than +1% after reaching an agreement to buy Warner Bros. Discovery's studio and streaming business [20]